Cargando…

Adherence with ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen supported by the use of a digital tablet dispenser with or without acoustic alarm: an open-label, randomized, multicenter study

OBJECTIVE: To evaluate the effect of a digital dispenser’s acoustic alarm function on adherence to ethinylestradiol (EE) 20 μg/drospirenone 3 mg in a flexible extended regimen (EE/drospirenone(Flex)) among women in five European countries (France, Germany, Italy, Spain, UK) seeking oral contraceptio...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiegratz, Inka, Elliesen, Jörg, Paoletti, Anna Maria, Walzer, Anja, Kirsch, Bodo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4294621/
https://www.ncbi.nlm.nih.gov/pubmed/25609999
http://dx.doi.org/10.2147/IJWH.S71906
_version_ 1782352738402697216
author Wiegratz, Inka
Elliesen, Jörg
Paoletti, Anna Maria
Walzer, Anja
Kirsch, Bodo
author_facet Wiegratz, Inka
Elliesen, Jörg
Paoletti, Anna Maria
Walzer, Anja
Kirsch, Bodo
author_sort Wiegratz, Inka
collection PubMed
description OBJECTIVE: To evaluate the effect of a digital dispenser’s acoustic alarm function on adherence to ethinylestradiol (EE) 20 μg/drospirenone 3 mg in a flexible extended regimen (EE/drospirenone(Flex)) among women in five European countries (France, Germany, Italy, Spain, UK) seeking oral contraception. STUDY DESIGN: Randomized, parallel-group open-label study. METHODS: Women aged 18–35 years received EE/drospirenone(Flex) administered in a regimen with cycle lengths of their choice with the aid of a digital pill dispenser over 1 year. In group A (N=250), the dispenser’s acoustic alarm was activated (ie, acoustic alarm + visual reminder). In group B (N=249), the acoustic alarm was deactivated (ie, visual reminder only). In addition, the women recorded pill intake daily in diary cards. The primary efficacy variable was the mean delay of daily pill release after the dispenser reminded the woman to take a pill (reference time). Secondary efficacy variables included number of missed pills, contraceptive efficacy, bleeding pattern, tolerability, and user satisfaction. RESULTS: Dispenser data showed a mean (standard deviation [SD]) daily delay in pill release of 88 (126) minutes in group A vs 178 (140) minutes in group B (P<0.0001). Median (lower quartile, Q1; upper quartile, Q3) number of missed pills was 0 (0; 1) in group A vs 4 (1; 9) in group B (P<0.0001). Diary card results revealed similar trends; however, underreporting of missed pills was evident in both groups. No pregnancies were reported during 424 women-years of exposure. Across the two groups, the mean (SD) EE/drospirenone(Flex) cycle length was 51.0 (31.8) days with strong regional differences, and the mean (SD) number of bleeding/spotting days was 50.4 (33.0) days. EE/drospirenone(Flex) was well tolerated, and 80% of women were satisfied with treatment. CONCLUSION: The dispenser’s activated acoustic alarm improved adherence with daily tablet intake of EE/drospirenone(Flex), reducing missed pills. EE/drospirenone(Flex) provided effective contraception and a good tolerability profile.
format Online
Article
Text
id pubmed-4294621
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-42946212015-01-21 Adherence with ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen supported by the use of a digital tablet dispenser with or without acoustic alarm: an open-label, randomized, multicenter study Wiegratz, Inka Elliesen, Jörg Paoletti, Anna Maria Walzer, Anja Kirsch, Bodo Int J Womens Health Original Research OBJECTIVE: To evaluate the effect of a digital dispenser’s acoustic alarm function on adherence to ethinylestradiol (EE) 20 μg/drospirenone 3 mg in a flexible extended regimen (EE/drospirenone(Flex)) among women in five European countries (France, Germany, Italy, Spain, UK) seeking oral contraception. STUDY DESIGN: Randomized, parallel-group open-label study. METHODS: Women aged 18–35 years received EE/drospirenone(Flex) administered in a regimen with cycle lengths of their choice with the aid of a digital pill dispenser over 1 year. In group A (N=250), the dispenser’s acoustic alarm was activated (ie, acoustic alarm + visual reminder). In group B (N=249), the acoustic alarm was deactivated (ie, visual reminder only). In addition, the women recorded pill intake daily in diary cards. The primary efficacy variable was the mean delay of daily pill release after the dispenser reminded the woman to take a pill (reference time). Secondary efficacy variables included number of missed pills, contraceptive efficacy, bleeding pattern, tolerability, and user satisfaction. RESULTS: Dispenser data showed a mean (standard deviation [SD]) daily delay in pill release of 88 (126) minutes in group A vs 178 (140) minutes in group B (P<0.0001). Median (lower quartile, Q1; upper quartile, Q3) number of missed pills was 0 (0; 1) in group A vs 4 (1; 9) in group B (P<0.0001). Diary card results revealed similar trends; however, underreporting of missed pills was evident in both groups. No pregnancies were reported during 424 women-years of exposure. Across the two groups, the mean (SD) EE/drospirenone(Flex) cycle length was 51.0 (31.8) days with strong regional differences, and the mean (SD) number of bleeding/spotting days was 50.4 (33.0) days. EE/drospirenone(Flex) was well tolerated, and 80% of women were satisfied with treatment. CONCLUSION: The dispenser’s activated acoustic alarm improved adherence with daily tablet intake of EE/drospirenone(Flex), reducing missed pills. EE/drospirenone(Flex) provided effective contraception and a good tolerability profile. Dove Medical Press 2015-01-05 /pmc/articles/PMC4294621/ /pubmed/25609999 http://dx.doi.org/10.2147/IJWH.S71906 Text en © 2015 Wiegratz et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Wiegratz, Inka
Elliesen, Jörg
Paoletti, Anna Maria
Walzer, Anja
Kirsch, Bodo
Adherence with ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen supported by the use of a digital tablet dispenser with or without acoustic alarm: an open-label, randomized, multicenter study
title Adherence with ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen supported by the use of a digital tablet dispenser with or without acoustic alarm: an open-label, randomized, multicenter study
title_full Adherence with ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen supported by the use of a digital tablet dispenser with or without acoustic alarm: an open-label, randomized, multicenter study
title_fullStr Adherence with ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen supported by the use of a digital tablet dispenser with or without acoustic alarm: an open-label, randomized, multicenter study
title_full_unstemmed Adherence with ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen supported by the use of a digital tablet dispenser with or without acoustic alarm: an open-label, randomized, multicenter study
title_short Adherence with ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen supported by the use of a digital tablet dispenser with or without acoustic alarm: an open-label, randomized, multicenter study
title_sort adherence with ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen supported by the use of a digital tablet dispenser with or without acoustic alarm: an open-label, randomized, multicenter study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4294621/
https://www.ncbi.nlm.nih.gov/pubmed/25609999
http://dx.doi.org/10.2147/IJWH.S71906
work_keys_str_mv AT wiegratzinka adherencewithethinylestradiol20mgdrospirenone3mginaflexibleextendedregimensupportedbytheuseofadigitaltabletdispenserwithorwithoutacousticalarmanopenlabelrandomizedmulticenterstudy
AT elliesenjorg adherencewithethinylestradiol20mgdrospirenone3mginaflexibleextendedregimensupportedbytheuseofadigitaltabletdispenserwithorwithoutacousticalarmanopenlabelrandomizedmulticenterstudy
AT paolettiannamaria adherencewithethinylestradiol20mgdrospirenone3mginaflexibleextendedregimensupportedbytheuseofadigitaltabletdispenserwithorwithoutacousticalarmanopenlabelrandomizedmulticenterstudy
AT walzeranja adherencewithethinylestradiol20mgdrospirenone3mginaflexibleextendedregimensupportedbytheuseofadigitaltabletdispenserwithorwithoutacousticalarmanopenlabelrandomizedmulticenterstudy
AT kirschbodo adherencewithethinylestradiol20mgdrospirenone3mginaflexibleextendedregimensupportedbytheuseofadigitaltabletdispenserwithorwithoutacousticalarmanopenlabelrandomizedmulticenterstudy